Rett syndrome (RTT) is an X-linked dominant neurodevelopmental disorder affecting 1 per 10,000-15,000 female births worldwide. The disease-causing gene has been identified as MECP2 (methylCpG-binding protein 2). In this study, we performed diagnostic mutational analysis of the MECP2 gene in RTT patients. Four exons and a putative promoter of the MECP2 gene were analyzed from the peripheral blood of 43 Korean patients with Rett syndrome by PCR-RFLP and direct sequencing. Mutations were detected in the MECP2 gene in approximately 60.5% of patients (26 cases/43 cases). The mutations consisted of 14 different types, including 9 missense mutations, 4 nonsense mutations and 1 frameshift mutation. Of these, three mutations (G161E, T311M, p385fsX409) were newly identified and were determined to be disease-causing mutations by PCR-RFLP and direct sequencing analysis. Most of the mutations were located within MBD (42.3%) and TRD (50%). T158M, R270X, and R306C mutations were identified at a high frequency. Additionally, an intronic SNP (IVS3 + 23C＞G) was newly identified in three of the patients. IVS3 + 23C＞G may be a disease-related and Korea-specific SNP for RTT. L100V and A201V are apparently disease-causing mutations in Korean RTT, contrary to previous studies. Disease-causing mutations and polymorphisms are important tools for diagnosing RTT in Koreans. The experimental procedures used in this study should be considered for clinical molecular biologic diagnosis.
Introduction
Rett syndrome (RTT, MIM No. 312750 ) is an X-linked dominant neurodevelopmental disorder and is the second most common cause of mental retardation in females, following Down syndrome (Rett, 1966; dos Santos et al., 2005) . The vast majority of cases of RTT (more than 99%) are sporadic occurrences and familial recurrences are rare (Hoffbuhr et al., 2001) .
RTT is caused by mutations in a gene encoding the methyl-CpG binding protein 2 (MECP2, AF30876) (Amir et al., 1999) . MECP2 is mapped between IRAK (interleukin-1 receptor associated kinase) and RCP (red opsin gene) loci on chromosome Xq28 (Reichwald et al., 2000) . It is 76 kb in size and is
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composed of 486 amino acids. The four exons of human MECP2 have a combined length of 1775 bp. MECP2 participates in transcriptional silencing by binding to methylated DNA in nucleosomes and chromatin. It contains functional domains, a methyl-CpG binding domain (MBD) of 85 amino acids that binds to methylated CpG islands, and a transcriptional repression domain (TRD) of 104 amino acids that interacts with the transcriptional repressor Sin3A, which recruits histone deacetylases (HDAC) (Van den Veyver and Zoghbi, 2000) . In addition, MECP2 has a nuclear localization signal (NLS) (Jorgensen and Bird, 2002) and a group II WW domain binding region (WDR) (Buschdorf and Stratling, 2004; Weaving et al., 2005) . The function of NLS within the TRD location is to facilitate the transport of MECP2 into the nucleus.
There are only a few reports regarding mutational analysis of MECP2 in Koreans because the overall understanding of RTT is limited (Chae et al., 2002) . To compare the pattern of MECP2 mutations in Koreans with RTT from worldwide reports, we performed mutational analysis in Korean RTT patients and control subjects. Direct DNA sequencing was used and results were confirmed by PCR-RFLP.
Materials and Methods

DNA samples from RTT patients
Whole blood samples (500 µl) from 43 sporadic RTT patients (41 females and 2 males) were collected in EDTA tubes. All patients were phenotypically classical RTT. Genomic DNA was extracted using an E.Z.N.A. blood DNA kit (Omega Bioteck Inc. Norcross).
PCR amplification
The putative promoter and four exons of the MECP2 gene were amplified by PCR by dividing exon 2 into two parts, exon 3 into two parts, and exon 4 into five parts. Primer sequences designed by Amir et al. (1999) were used, except for the putative promoter and exon 1. The sequence of the promoter and exon 1 were 5'-gggTgCAATgAAACgCTTA-3' (forward) and 5'-TTTACCACAgCCCTCTCTCC-3' (reverse).
Direct sequencing
The PCR products were cleaned using a QIAquick gel extraction kit (QIAGEN, Hiden, Germany). The sequencing primers were the same as those for PCR. The DNA sequencing results were compared with the normal DNA sequence (AF030876).
RFLP analysis
We used the GeneTyx program to investigate the restriction enzyme sites. Dde I (New England Biolabs Co., MA) was used to detect G161E. BsmB I (New England Biolabs.) was used to detect T311M. A mismatch PCR technique was used to determine if the L100V is a disease-causing mutation. A second new reverse primer of exon 3 for the L100V mutation was designed (5'-GCTTAAGCTTCCGTGTCCAGC-CTTCAGGTA-3'). The primer sequence for mismatch PCR is underlined. The PCR product for (Fyfe et al., 2003) . Circles (○, ) represent missense mutations and squares ( , ) represent nonsense mutations. Mutations at CpG dinucleotides are shown by filled circles ( ) or squares ( ). Frequency is indicated by the number of symbols (Buyse et al., 2000; Miltenberger-Miltenyi and Laccone, 2003; Fukuda et al., 2005; Oexle et al., 2005) . L100V in the MECP2 gene created an Afa I (Takara, Tokyo, Japan) restriction site. A201V created a Bal I (Takara) restriction site. Restriction digested products were separated by electrophoresis on either 2% agarose gel or 4% NuSieve gel (FMC, Rockland) (Bedia et al., 2003; Kim et al., 2004) .
Results
Mutational analysis of MECP2
To investigate mutation of the MECP2 gene, we analyzed a promoter and four exons of MECP2 in 43 RTT patients by direct sequencing. The amplified PCR product contained an intron and an exon. MECP2 mutations were detected in 26 (60.5%) of the 43 patients. These results were compared with the MECP2 variation database for InterRETT and RettBASE (Fyfe et al., 2003) . The mutations consisted of 14 different types, including 9 missense mutations, 4 nonsense mutations, and 1 frameshift mutation. Most of these mutations were located within MBD (42.3%) and TRD (50%) (Figure 1 ). Of the mutations identified, three (G161E, T311M, P385fsX409) were new ( Figure 2 ). Three mutations, T158M (9.3%), R270X (11.6%), and R306C (7%), were identified with a high frequency ( Table 1) . The two male patients with different RTT phenotypes did not have any identifiable mutations. Two silent mutations (F142F, T442T) that had been reported previously (Miltenberger-Miltenyi and Laccone, 2003) were also found. These accompanied other mutations in three of the four patients with F142F and T442T.
Confirmation of the mutations
To confirm the novel sequence changes, RFLP analysis was performed for G161E and T311A (Table 1 ) and direct sequencing was performed for p385fsX409. The G161E (c.482G＞A) mutation created a Dde I site while the wild type had 241 bp and 129 bp fragments, and the heterozygotic mutant had 241 bp, 202 bp, 129 bp, and 39 bp fragments ( Figure 3A , lane 5 and 6). The T311A (c.932C＞T) mutation destroyed the BsmB I site. The 366 bp product was digested into 198 bp and 168 bp fragments in the wild type ( Figure 3A , lane 8), whereas patients with T311A exhibited a single band Exon3 (2) Exon4 (1) Exon4 (1) Exon4 (1) Exon4 (1) Exon4 (1) Exon4 (3) Exon4 (3) Exon4 ( Exon4 (2) Exon4 (3) Exon4 (3) c.502C Figure 3A , lane 9). The novel deletion mutation p385fsX409 (1153del44bp) was not identified by direct sequence mutational screening of exon 4 in the control samples. All of these base substitutions were absent in more than 100 control individuals. The RFLP and direct sequencing data indicate that these DNA variants are potential disease-causing mutations. L100V (c.298C＞G), one of these previously predicted substitutions, has been reported to be an unclassified variant associated with RTT (Buyse et al., 2000) . Mismatch PCR was performed to determine whether L100V is also SNP in Korea. After amplification with the mismatch primers, the wild type sequence CCCTACCTGAA was generated. The generated mutant sequence CCG/TACCT-GAA created an Afa I site. The 199 bp product was cut into pieces of 170 bp and 29 bp ( Figure 3A , lane 2 and 3). Additionally, A201V (c.602C＞T) has been reported to be a Japanese-specific characteristic because the mutation occurs in the normal Japanese population (Fukuda et al., 2005) . The 279 bp product with A201V was cut into 227 bp and 52 bp fragments by Bal I ( Figure 3B , lane 2~10). L100V and A201V were absent in more than 100 normal control subjects and, therefore, were thought to be disease-causing mutations.
Single nucleotide polymorphism (SNP) of the MECP2 gene IVS3 + 23C＞G (g.C65494G) was observed in only three patients (7%) (Figure 4) . The novel SNP accompanied other mutations in two of the patients.
Discussion
In classical cases, the mutation rate approaches 80% with lower rates in atypical cases (30%) (Hoffbuhr et al., 2001) . There is no clear correlation between the type and position of mutations, although MECP2 plays a pivotal role in the RTT phenotype (Weaving et al., 2003) . We identified mutations of the MECP2 gene in 60.5% (26/43 cases) of the patients (Table 1 ). The mutational frequency was lower in our results than in previous studies due to the inclusion of patients with various phenotypes of RTT, and not limiting subjects to classical cases, as in previous reports. Most mutations were identified in the functional domains (25/26, 96.2%) MBD, TRD and WDR, and, therefore, probably critically affect the function of MECP2. We identified three novel mutations that cause amino acid substitutions (G161E, T311M, P385fsX409). G161E was found in MBD, T311M in TRD, and P385fsX409 in WDR of the C-terminus. The G161E substitution resulted in an alteration of a charge from neutral to negative The SNP identified in this study, Bottom: SNPs described by others (Buyse et al., 2000; Fukuda et al., 2005 To predict whether the observed changes were mutations or polymorphism, PCR-RFLP analysis of G161E and T311M was performed. Direct sequencing was used to analyze P385fsX409. These mutations were not found in more than 100 control subjects. Therefore, G161E, T311M, and P385fsX409 are probably disease-causing mutations. Previous studies reported that L100V and A201V are the unclassified sequence and the SNP (Buyse et al., 2000; Fukuda et al., 2005) , respectively. The alleles did not appear in more than 100 Korean control subjects. L100V and A201V were identified as possible disease-causing mutations from RFLP analysis in Korean RTT patients, which is contrary to previous reports. No mutation in MECP2 was found in the two male RTT patients in our study. Mutations in MECP2 in most males are lethal (Orrico et al., 2000) . The infrequent occurrence of RTT in males has been explained by the existence of somatic mosaicism for an RTT-causing MECP2 mutation (Jellinger, 2003) . We identified two silent mutations (F142F, T442T) and an intronic SNP (IVS3 + 23C＞G) of the gene. The silent mutations are probably not responsible for the disease phenotype although they were associated with other mutations, except in one patient. IVS3 + 23C＞G was observed in only three RTT patients (7%) and was not observed in control subjects. It is possible that IVS3 + 23C＞G is a disease-related and Korea-specific SNP for RTT. The novel SNP accompanied other mutations in two of the patients. This polymorphism probably results in phenotypic variability or susceptibility to RTT, even though it is an intronic SNP.
Mutation in MECP2 is not synonymous with RTT, and RTT is not always caused by an identifiable mutation in MECP2 (Miltenberger-Miltenyi and Laccone, 2003) . Recently, studies have suggested a relationship between RTT and MECP2 in the regulation of UBE3A (Ubiquitin-Protein ligase E3A), GABRB3 (the beta3 subunit of the GABAA receptor) and CDKL5 (Cyclin-dependent kinase-like5) expression (Fan G and Hutnick L, 2005; Milani et al., 2005; Samaco et al., 2005; Segawa and Nomura, 2005) . In this study, we did not detect any mutations of MECP2 in seventeen of the patients. These cases should be analyzed for mutations of other candidate genes, followed by functional analysis of these genes, as well as MECP2.
PCR-RFLP is an essential step in determining whether the observed changes to the MECP2 gene are mutations or polymorphisms. Disease-causing mutations and polymorphisms are important for diagnosing RTT in Koreans. The experimental procedures used in this study should be considered for molecular biologic diagnosis in the clinical field.
